Home › Funds › Caligan Partners LP › IVA
Caligan Partners LP position in IVA
INVENTIVA SA · Health Care
Caligan Partners LP reported holding 9,185,935 shares of IVA (INVENTIVA SA) in its Q3 2026 13F filing — a position valued at US$33.9M, representing 2.07% of its reported portfolio and ranking #13 among its reported holdings. Caligan Partners LP has disclosed IVA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's IVA position evolved
Caligan Partners LP first disclosed a stake in IVA in Q4 2025 at 2,000,000 shares (US$9.3M). The position peaked in Q3 2026 at 9,185,935 shares, worth US$33.9M. Across 4 filings, Caligan Partners LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 9,185,935 shares valued at US$33.9M — an increase of 1,022,744 shares quarter over quarter.. Notable position changes include a 149% increase in Q1 2026 (shares fell 32% over the following quarter), a 64% increase in Q2 2026 (shares fell 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.00M | $9.30M | New |
| Q1 2026 | 4.97M | $27.61M | Add |
| Q2 2026 | 8.16M | $30.86M | Add |
| Q3 2026 | 9.19M | $33.90M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IVA and 13F data
IVA (INVENTIVA SA) is a Health Care company. 82 other funds we track also report a position in IVA — the largest reported positions include Samsara BioCapital, LLC (US$23.3M), Andera Partners (US$13.4M), SymBiosis Capital Partners, LLC (US$13.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IVA
- Samsara BioCapital, LLC 6.31M sh · $23.30M · Q3 2026
- Andera Partners 3.63M sh · $13.41M · Q3 2026
- SymBiosis Capital Partners, LLC 2.35M sh · $13.06M · Q1 2026
- Trails Edge Capital Partners, LP 2.66M sh · $9.81M · Q3 2026
- Squadron Capital Management LLC 2.40M sh · $8.86M · Q3 2026
- Logos Global Management LP 2.00M sh · $7.38M · Q3 2026
- NEXTBio Capital Management LP 1.79M sh · $6.60M · Q3 2026
- Yu Fan 1.50M sh · $5.54M · Q3 2026
- NEA Management Company, LLC 1.46M sh · $5.40M · Q3 2026
- Patient Square Capital LP 1.22M sh · $4.51M · Q3 2026
- Propel Bio Management, LLC 1.13M sh · $4.18M · Q3 2026
- Paradigm Biocapital Advisors LP 808.18K sh · $2.98M · Q3 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held IVA?
Caligan Partners LP has disclosed IVA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Caligan Partners LP's current position in IVA?
As of Q3 2026, Caligan Partners LP holds 9.19M shares of IVA (INVENTIVA SA), valued at $33.90M, representing 2.07% of its reported portfolio and ranking #13.
Has Caligan Partners LP been buying or selling IVA?
In the latest 13F filing (Q3 2026), Caligan Partners LP increased its position in IVA. The position peaked in Q3 2026 at 9.19M shares.
Which other funds hold IVA?
Other major institutional holders of IVA include Samsara BioCapital, LLC, Andera Partners, SymBiosis Capital Partners, LLC, among 82 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.